Long‑term remission under Disitamab Vedotin (RC48) in HR‑positive/HER2‑positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report-Reference-Cited by-同舟云学术

Long‑term remission under Disitamab Vedotin (RC48) in HR‑positive/HER2‑positive metastatic breast cancer with brain meningeal, and bone marrow involvement: A case report

Published:2022-08-12 Issue:4 Volume:24 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Wu Qifeng¹,He Lina²,Luo Jing³,Jin Wen³,Xu Yingchun²,Wang Chen³

Affiliation:

1. School of Medicine, Shanghai Jiaotong University, Shanghai 200127, P.R. China

2. Department of Oncology, Renji Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai 200127, P.R. China

3. Department of Oncology, Minhang Branch, Zhongshan Hospital, Fudan University, Shanghai 201100, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Reference35 articles.

1. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

2. The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis;Moasser;Oncogene,2007

3. Breast cancer;Harbeck;Nat Rev Dis Primers,2019

4. Brain metastases;Klos;Neurologist,2004

5. Metastatic behavior of breast cancer subtypes;Kennecke;J Clin Oncol,2010

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: outcome of anlotinib treatment in breast cancer patient with brain metastases;Frontiers in Pharmacology;2024-08-19

2. Partial response to trastuzumab deruxtecan (DS8201) following progression in HER2-amplified breast cancer with pulmonary metastases managed with disitamab vedotin (RC48): a comprehensive case report and literature review;Frontiers in Oncology;2024-06-17

3. Antineoplastics/loperamide;Reactions Weekly;2022-10-01